CAJ | 학술논문

目的研究非那雄胺在晚期前列腺癌间歇性雄激素阻断(IAB)治疗间隙期的应用是否能延缓晚期前列腺癌的疾病进展. 方法 87例晚期前列腺癌患者分2组,A组49例行单纯IAB治疗,B组38例在IAB治疗的基础上间歇期采用非那雄胺治疗.比较2组患者的疾病治疗周期和疾病进展时间. 结果 A组患者共完成89个治疗周期,平均治疗周期为(12.8±5.4)个月,其中治疗期为(6.6±3.5)个月,间歇期为(7.1±4.8)个月;B组患者共完成85个治疗周期,平均治疗周期为(15.3±5.9)个月,其中治疗期为(6.9±3.2)个月,间歇期为(9.2±3.9)个月;B组治疗周期和间歇期长度大于A组(P=0.0428,P=0.03).B组3年疾病进展率(28.4±2.7)%,低于A组的(34.8±3.5)%(P=0.0350). 结论非那雄胺在晚期前列腺癌间歇性IAB间隙期的应用能延缓晚期前列腺癌的疾病进展.
목적 연구비나웅알재만기전렬선암간헐성웅격소조단(IAB)치료간극기적응용시부능연완만기전렬선암적질병진전. 방법 87례만기전렬선암환자분2조,A조49례행단순IAB치료,B조38례재IAB치료적기출상간헐기채용비나웅알치료.비교2조환자적질병치료주기화질병진전시간. 결과 A조환자공완성89개치료주기,평균치료주기위(12.8±5.4)개월,기중치료기위(6.6±3.5)개월,간헐기위(7.1±4.8)개월;B조환자공완성85개치료주기,평균치료주기위(15.3±5.9)개월,기중치료기위(6.9±3.2)개월,간헐기위(9.2±3.9)개월;B조치료주기화간헐기장도대우A조(P=0.0428,P=0.03).B조3년질병진전솔(28.4±2.7)%,저우A조적(34.8±3.5)%(P=0.0350). 결론 비나웅알재만기전렬선암간헐성IAB간극기적응용능연완만기전렬선암적질병진전.
Objective To investigate the finasteride application during the off-cycle of intermittent androgen blockade (IAB) in patients with advanced prostate cancer treated with IAB.Methods Eighty-seven patients with advanced prostate cancer were divided into two groups: forty-nine patients received IAB (group A), and thirty-eight patients underwent IAB and finasteride during the off-cycle of IAB (group B). The time of treatment cycle and the time to disease progression were compared between the two groups. Results The patients in group A completed 89 treatment cycles and the mean cycle length was (12.8±5.4) months [treatment time and non-treatment time were (6.6±3.5) months and (7.1±4.8) months, respectively]. The patients in group B completed 85 cycles and the mean cycle length was (15.3±5.9) months [treatment time and non-treatment time were (6.9±3.2) months and (9.2v±3.9) months, respectively]. There was a significant difference between group A and B in the mean cycle length and the non-treatment time (P=0.0428,P=0.03).The 3-year progression rate was ( 34.8±3.5 )% in group A and ( 28.4±2.7)% in groups B ( P=0.035). Conclusions The application of finasteride during the off-cycle of IAB in patients with advanced prostate cancer treated with intermittent androgen blockade (IAB) can delay progression of advanced prostate cancer.